KR102868881B1 - 운동선수의 오버트레이닝을 예방 또는 치료하는데 사용하기 위한 화합물 - Google Patents

운동선수의 오버트레이닝을 예방 또는 치료하는데 사용하기 위한 화합물

Info

Publication number
KR102868881B1
KR102868881B1 KR1020217013546A KR20217013546A KR102868881B1 KR 102868881 B1 KR102868881 B1 KR 102868881B1 KR 1020217013546 A KR1020217013546 A KR 1020217013546A KR 20217013546 A KR20217013546 A KR 20217013546A KR 102868881 B1 KR102868881 B1 KR 102868881B1
Authority
KR
South Korea
Prior art keywords
overtraining
composition
hydroxybutyrate
paragraph
ketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217013546A
Other languages
English (en)
Korean (ko)
Other versions
KR20210079304A (ko
Inventor
키에란 클라크
피터 헤스펠
Original Assignee
티델타스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티델타스 리미티드 filed Critical 티델타스 리미티드
Publication of KR20210079304A publication Critical patent/KR20210079304A/ko
Application granted granted Critical
Publication of KR102868881B1 publication Critical patent/KR102868881B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020217013546A 2018-10-04 2019-10-03 운동선수의 오버트레이닝을 예방 또는 치료하는데 사용하기 위한 화합물 Active KR102868881B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816196.8 2018-10-04
GB1816196.8A GB2577723A (en) 2018-10-04 2018-10-04 Compounds for new use
PCT/GB2019/052797 WO2020070506A1 (en) 2018-10-04 2019-10-03 Compounds for use in preventing or treating athlete overtraining

Publications (2)

Publication Number Publication Date
KR20210079304A KR20210079304A (ko) 2021-06-29
KR102868881B1 true KR102868881B1 (ko) 2025-10-15

Family

ID=68242730

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013546A Active KR102868881B1 (ko) 2018-10-04 2019-10-03 운동선수의 오버트레이닝을 예방 또는 치료하는데 사용하기 위한 화합물

Country Status (9)

Country Link
US (1) US12290496B2 (https=)
EP (1) EP3860584B1 (https=)
JP (1) JP7575163B2 (https=)
KR (1) KR102868881B1 (https=)
CN (1) CN112996498B (https=)
AU (1) AU2019351925B2 (https=)
CA (1) CA3114889A1 (https=)
GB (2) GB2577723A (https=)
WO (1) WO2020070506A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100020441A1 (it) 2021-07-30 2023-01-30 Unichem Estense S R L Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici
MX2024005533A (es) * 2021-11-12 2024-07-29 Arxada Ag Compuestos derivados de polioles.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514104A (ja) * 2012-04-05 2015-05-18 ティーデルタエス リミテッド 筋パワー出力を維持又は改善するためのケトン体及びケトン体エステル

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
EP1648952B1 (en) 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
SE0400355D0 (sv) 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
EP1778213B1 (en) 2004-07-16 2017-04-05 BTG International Limited A method for the synthesis of oligomeric compounds
WO2006020179A2 (en) 2004-07-20 2006-02-23 Ketocytonyx Inc. Oligomeric ketone compounds
CN100344280C (zh) * 2005-08-01 2007-10-24 清华大学 3－羟基丁酸及其衍生物的新用途
CN101489543A (zh) 2007-03-14 2009-07-22 汕头大学 提高受试者的学习和/或记忆能力的3-羟基脂肪酸及其衍生物
DK2240017T3 (da) 2008-01-04 2019-06-17 Univ Oxford Innovation Ltd Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
EP3296284B1 (en) 2008-08-21 2021-12-01 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Non-therapeutical use of hydroxybutyrate ester
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
SG11201507685UA (en) 2013-03-14 2015-10-29 Isis Innovation Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
KR102499654B1 (ko) 2013-03-19 2023-02-13 유니버시티 오브 사우스 플로리다 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
GB201314127D0 (en) 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
US20150283163A1 (en) 2014-04-04 2015-10-08 Organic Medical Ventures, L.L.C. Muscle treatment composition and method making same
WO2016123229A1 (en) 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CA3021784A1 (en) 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514104A (ja) * 2012-04-05 2015-05-18 ティーデルタエス リミテッド 筋パワー出力を維持又は改善するためのケトン体及びケトン体エステル

Also Published As

Publication number Publication date
EP3860584A1 (en) 2021-08-11
US20210338612A1 (en) 2021-11-04
GB2592803B (en) 2022-11-09
CA3114889A1 (en) 2020-04-09
CN112996498A (zh) 2021-06-18
WO2020070506A1 (en) 2020-04-09
US12290496B2 (en) 2025-05-06
GB202105967D0 (en) 2021-06-09
JP7575163B2 (ja) 2024-10-29
GB2577723A (en) 2020-04-08
GB2592803A (en) 2021-09-08
CN112996498B (zh) 2024-10-29
EP3860584B1 (en) 2026-02-18
AU2019351925B2 (en) 2024-12-05
KR20210079304A (ko) 2021-06-29
JP2022504207A (ja) 2022-01-13
AU2019351925A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
AU2021240302B2 (en) Ketone body and ketone body ester for reducing muscle breakdown
JP6241956B2 (ja) 筋パワー出力を維持又は改善するためのケトン体及びケトン体エステル
CA2703693C (en) Anti-fatigue agent comprising amino acid composition
CN101646358B (zh) 含有a-酮酸的食品补充剂
US20100280123A1 (en) Food supplement containing alpha-keto acids for supporting diabetes therapy
JP2013520454A (ja) 栄養組成物
KR101734152B1 (ko) 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
CN111132674A (zh) 治疗方法
KR102868881B1 (ko) 운동선수의 오버트레이닝을 예방 또는 치료하는데 사용하기 위한 화합물
WO2019234402A1 (en) Compounds for use in cancer cachexia
EP3622951A1 (en) Agent for raising total ketone concentration, oil and fat composition, pharmaceutical composition, and food product composition
HK1225965B (en) Ketone body and ketone body ester for reducing muscle breakdown
HK1206999B (en) Ketone bodies and ketone body esters for maintaining or improving muscle power output

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)